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Purpose.Toevaluateinchronicallyhaemodialysedpatients(CHPs),if:(1)thevascularaccess(VA)position(upperarmorforearm)
is associated with diﬀerential changes in upper limb arterial stiﬀness; (2) diﬀerences in arterial stiﬀness exist between genders
associated with the VA; (3) the vascular substitute (VS) of choice, in biomechanical terms, depends on the previous VA location
and CHP gender. Methods. 38 CHPs (18 males; VA in upper arm: 18) were studied. Left and right carotid-brachial pulse wave
velocity (PWVc-b) was measured. In in vitro studies, PWV was obtained in ePTFE prostheses and in several arterial and venous
homografts obtained from donors. The biomechanical mismatch (BM) between CHP native vessel (NV) and VS was calculated.
Results/Conclusions.P W V c-b in upper limbs with VA was lower than in the intact contralateral limbs (P<0.05), and diﬀerences
were higher (P<0.05) when the VA was performed in the upper arm. Diﬀerences between PWVc-b in upper limbs with VA (in the
upper arm) with respect to intact upper limbs were higher (P<0.05) in males. Independently of the region in which the VA was
performed, the homograft that ensured the minimal BM was the brachial artery. The BM was highly dependent on gender and the
location in the upper limb in which the VA was performed.
1.Introduction
We have recently demonstrated that, in chronically haemo-
dialysed patients (CHP), the vascular accesses determine
signiﬁcant changes in the upper limb native arteries’ stiﬀness
[1]. More precisely, arterial stiﬀness values measured in
the arterial pathway of the upper limb where the vascular
access was constructed were lower than those measured in its
contralateral limb with intact arteries (i.e., without vascular
access). Changes in arterial diameter and blood ﬂow asso-
ciated with the vascular access construction and maturation
have been pointed out as factors related with arterial stiﬀness
variations in the upper limbs where a vascular access was
performed[1]. Then, theoretically, there could be diﬀerences
in the carotid-brachial pathway stiﬀness between patients
with arteriovenous ﬁstulae (AVF) in the upper arm and
those with vascular access in the forearm; with high stiﬀness
reduction when the AVF is constructed in the upper arm.
In addition, taking into account the gender dependence of
arterial stiﬀness variations and vascular access performance
[2, 3], it would be important to explore possible vascular
biomechanical diﬀerences between male and female CHP.2 International Journal of Nephrology
Findings regarding gender-associated diﬀerences in arterial
response to vascular access construction could contribute to
understandgenderdiﬀerencesintheAVFpatencyrates[2,3].
Native vessels are the conduits of ﬁrst choice in perform-
ing vascular accesses for haemodialysis, arterial reconstruc-
tion,andbypassing.However,inCHP,nativevesselsareoften
damagedornotavailable;therefore,theonlycurrentalterna-
tive is expanded polytetraﬂuoroethylene (ePTFE) prostheses.
This choice is very far from the ideal solution because of
their poor patency rates [4, 5]. In this context, there is great
interest in developing unconventional vascular substitutes to
be used employed in the construction of vascular accesses in
CHP.
Intimal hyperplasia stenosis in the native vessel-vascular
substitute anastomotic region is the Achilles’ heel for most
vascular accesses in CHP. It is determined, among other fac-
tors, by native vessel-vascular substitute biomechanical mis-
match (BM) [6]. Hence, the vascular substitute should have
similar mechanical properties to those of the CHP native
vessels [7–9]. We have previously demonstrated that cryop-
reservation procedures preserve the mechanical properties of
fresh human muscular and elastic arteries and veins [10–12];
therefore, fresh or cryopreserved vessels could be used as an
alternative in vascular access construction, resulting in BM
improvement. Furthermore, we have demonstrated that BM
betweenanupperlimbnativearteryandavascularsubstitute
can be minimized by selecting the most adequate type of
vascular homograft [13]. Homografts have been used in by-
pass and VA construction [14–17]; nonetheless, the selection
of the most appropriate homograft capable to minimize the
BM in CHP upper limbs should be evaluated, taking into
account gender and previous vascular access placement.
The purposes of this work were to evaluate, in CHP
(1) if vascular access position (upper arm or forearm)
is associated with variations in upper limb arterial
stiﬀness,
(2) the potential gender-associated diﬀerences in arterial
stiﬀness changes related to the vascular access posi-
tion, and,
(3) if the vascular substitute of choice, in terms of
its BM with respect to native arteries, depends on
(a) previous vascular access location and (b) CHP
gender.
2. Methods
This study was approved by our Institutional Review Board
and Ethics Committee. Patients gave written agreement for
noninvasive studies and documented consent was obtained
for the vascular homograft procurement from deceased
humanmultiorgandonors accordingto no. 14005and17668
legal rules of the Uruguay.
2.1. Noninvasive Studies in Chronically Haemodialysed Pa-
tients. Pulse wave velocity (PWV) was measured in 38 (18
males and 20 females) ambulatory patients (age: 53 ± 17
yearsold)whohadAVFforhaemodialysisintheupperlimbs,
at upper arm (n = 18), and forearm (n = 20) level. The term
upper limb was used to deﬁne the anatomic region between
the shoulder and the wrist joints. The terms upper arm and
forearm were used to deﬁne the part of the upper limb
between the shoulder and the elbow joints, and between the
elbow and the wrist joints, respectively. Haemodialysis was
performed in the morning three times a week during 4 to
5 hours, on standard bicarbonate bath. Patients had been
submitted to renal function substitutive therapy for 66 ±
56 months (Table 1).
In all cases, clinical data (heart rate, brachial blood
pressure, weight, age, height, hip, and waist perimeter)
were obtained by the same observer previous to the PWV
measurements. Body mass index (BMI) and waist-to-hip
ratio were calculated for all patients.
The carotid-femoral and right and left carotid-brachial
PWV measurements were performed in a stable environ-
m e n t ,a si np r e v i o u sw o r k s[ 1, 13]. The carotid-femoral
PWV, a predictor of cardiovascular events, was measured to
characterize the aortic stiﬀness in our patients and to
compare the obtained values with those expected in healthy
people [18, 19]. The carotid-brachial PWV is not a predictor
of cardiovascular events, but it is a technique widely used
to noninvasively characterize the upper limb arterial stiﬀ-
ness. PWV measurements were performed using two high-
ﬁdelity strain gauges mechanotransducers (Motorola MPX
2050, Motorola Inc., Corporate 1303 E. Algonquin Road,
Schaumburg, IL 60196, USA) connected to an electronic
signal ampliﬁerdevice[17]. Bothmechano-transducerswere
simultaneously positioned on the skin over the carotid-
femoral or carotid-brachial arteries. Signals from the same
arterial pathway were acquired and analysed using software
developed in our laboratory, which calculates the time delay
between instantaneous arterial pulse waves. The time delay
between the femoral and carotid waveforms or between
the carotid and brachial waveforms (pulse transit time)
was quantiﬁed using the point of maximal upstroke during
systole. The direct distance between the recording sites was
used to quantify the PWV. Then, using time delay data and
the distance between the sensors, the arterial pathway PWV
was calculated. In all patients, according to the methodology
previously described by our group, several PWV measure-
mentswereobtainedfromasinglecontinuousrecordingthat
included at least ten cardiac cycles [1].
Finally, blood was drawn from each patient and routine
chemical analyses were performed to quantify haematocrit,
haemoglobin, serum albumin, serum creatinine, calcium,
phosphate, parathyroid hormone (PTH), urea, total choles-
terol, HDL and LDL cholesterol, and triglycerides (Table 1).
Serum creatinine was measured by the modiﬁed kinetic Jaﬀe
reaction and recalibrated in order to calculate the estimated
glomerular ﬁltration rate (eGFR) using the Modiﬁcation of
Diet in Renal Disease (MDRD) Study formula [20]:
eGFR = 186 ·

serum creatinine
mg
dL
−1.154
·age−0,203 ·(0.742 if female).
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Table 1: Clinical characteristics, biochemical and arterial parameter measurements.
CHP
AVF at the
forearm
(n = 20)
CHP
AVF at the
upper arm
(n = 18)
CHP AVF at the upper arm (n = 18)
Females
(n = 10)
Males
(n = 8)
Mean ± SD Mean ± SD  %w i t hr e s p e c tt o
AVF in the upper arm Mean ± SD Mean ± SD
 % with
respect to
females
Age (years) 52.2 ± 4.3 51.9 ± 6.3 1 55.3 ± 7.7 45.0 ± 12.1 23
Height (m) 1.63 ± 0.03 1.69 ± 0.03 −31 . 6 4 ± 0.03 1.77 ± 0.04 −7∗
Body weight (kg) 66.8 ± 3.4 62.9 ± 3.6 6 60.2 ± 2.5 68.3 ± 10.0 −12
BMI (kg/m2) 24.9 ± 1.0 22.1 ± 0.9 13 22.3 ± 1.0 21.6 ± 2.2 3
Waist circumference (cm) 91.2 ± 3.9 87.0 ± 2.1 5 87.3 ± 2.3 86.3 ± 4.9 1
Hip circumference (cm) 90.5 ± 1.7 91.4 ± 2.4 −1 90.6 ± 3.3 93.0 ± 3.2 −3
Waist/hip ratio 1.01 ± 0.04 0.96 ± 0.04 6 0.97 ± 0.05 0.93 ± 0.03 5
Hematocrit (%) 32.6 ± 1.5 33.7 ± 1.5 −3 31.9 ± 0.8 37.2 ± 3.9 −14∗
Hemoglobin (g/dL) 10.3 ± 0.6 10.9 ± 0.5 −5 10.3 ± 0.4 12.1 ± 1.1 −15∗
Serum albumin (g/dL) 4.0 ± 0.1 4.0 ± 0.2 −13 . 9 ± 0.1 4.3 ± 0.5 −10
Calcium (mg/dL) 9.5 ± 0.2 9.3 ± 0.2 2 9.3 ± 0.3 9.2 ± 0.1 1
Serum creatinine (mg/dL) 10.0 ± 0.8 9.7 ± 0.6 3 9.3 ± 0.6 10.6 ± 1.3 −12
eGFR (mL/min/1.73m2)5 . 1 6 ± 0.41 4.87 ± 0.25 6 4.79 ± 0,29 5.09 ± 0.66 −6
Phosphates (mg/dL) 5.0 ± 0.2 5.2 ± 0.3 −35 . 1 ± 0.4 5.5 ± 0.1 −7
Parathyroid hormone
(pg/mL) 393.7 ± 75.0 232.4 ± 46.3 69∗∗ 268.2 ± 57.0 160.9 ± 75.3 67∗
Serum urea (mg/dL) 152.3 ± 8.8 140.4 ± 10.1 8 132.5 ± 9.6 156.3 ± 23.7 −15
Total cholesterol (mg/dL) 175.7 ± 11.3 209.2 ± 23.7 −16 209.0 ± 36.0 209.7 ± 16.5 0
HDL cholesterol (mg/dL) 40.1 ± 3.5 41.9 ± 2.2 −4 41.2 ± 2.6 43.3 ± 4.9 −5
LDL cholesterol (mg/dL) 111.4 ± 8.5 119.6 ± 12.5 −7 124.8 ± 15.8 109.0 ± 23.1 15
Total triglycerides (mg/dL) 184.2 ± 26.8 210.8 ± 34.7 −13 196.5 ± 51.8 239.3 ± 19.2 −18
Systolic blood pressure
(mmHg) 128.2 ± 5.16 133.3 ± 6.24 −4 136.7 ± 5.58 126.7 ±
16.67 8
Diastolic blood pressure
(mmHg) 73.5 ± 3.53 71.1 ± 4.23 3 73.3 ± 4.94 66.7 ± 8.82 10
Heart rate (beats/min) 85.9 ± 3.35 89.9 ± 4.27 −4 88.0 ± 2.35 93.7 ± 13.45 −6
Carotid-femoral PWV
(m/s) 13.5 ± 0.69 14.8 ± 1.16 −9 14.9 ± 1.58 14.4 ± 1.73 4
Mean values ±standarddeviation(SD).CHP:chronicallyhemodialysedpatients.AVF:arterio-venousﬁstula.BMI:bodymassindex.PWV:pulsewavevelocity
measured in carotid-femoral pathway. Blood Urea Nitrogen (BUN, mg/dl) = urea [mg/dl] divided by 2.14. eGFR: estimated glomerular ﬁltration rate
calculated using the modiﬁcation of diet in renal disease (MDRD) formula. ∗∗P < 0.05 with respect to the group with AVF at forearm level. ∗P < 0.05
with respect to female group with AVF at upper arm level.
2.2. In Vitro Studies in Vascular Substitutes: ePTFE Prostheses
and Homografts. In this study we included both biological
(i.e., vascular homografts) and synthetic (i.e., ePTFE) vas-
cular substitutes. We obtained vascular segments (5cm in
length) from 10 deceased human multiorgan donors aged
31 ± 5 years: saphenous vein, femoral (muscular homo-
graft), carotid (elastic homograft), and brachial (transitional
homograft) arteries. Vascular segments were submitted to
a biomechanical in vitro study [10–13]. Vessel harvesting
techniques were in agreement with ethical and safety issues
for therapeutic use. In all cases, documented consent was
obtained according to no. 14005 and no. 17668 legal rules
of Uruguay. Exclusion criteria agreed with the International
Atomic Energy Agency (International Standards for Tissue
Banks), the American Association for Tissue Bank, and the
European Association for Tissue Bank.
In vitro dynamic analyses were performed in homografts
and in 6 ePTFE (Gore-Tex Vascular graft, W. L. Gore &
Associates, Inc., Flagstaﬀ, AZ, USA) segments (5 to 6cm in
length). All conduits were mounted in a mock circulation
loop and were maintained, immersed in, and perfused
with Tyrode’s solution (37◦C, pH = 7.4, oxygenated) in a4 International Journal of Nephrology
specimen chamber. The mock circulation loop consisted
of polyethylene tubing, with ﬂuid circulation powered by
a pneumatic pump (Jarvik Model 5, Kolﬀ Medical Inc.,
Salt Lake City, UT, USA) that allowed pressure value and
waveform adjustments. Intraluminal pressure was measured
with a solid-state transducer (1200Hz frequency response,
K¨ onigsberg Instruments, Inc., Pasadena, CA, USA). The
segments’ external diameter was measured with ultrasonic
crystals (5MHz, 2mm diameter) [21]. The ultrasonic signal
transit time, obtained during the experiment, was converted
into distance by means of a sonomicrometer (Triton Tech-
nology Inc. San Diego, CA, USA). As in previous works
[10–13, 17, 21], taking into account the speed of sound in
biological tissues and in experimental media used in arterial
in vitro studies, and considering our experimental conditions
(i.e., temperature, vascular smooth muscle reactivity), we
assumed a sound speed of 1580m/s [22, 23].
After being placed in the specimen chamber, all segments
were allowed to equilibrate under steady state ﬂow and pres-
sure. The simulated haemodynamic conditions mimicked
those of the CHP included in the study, ensuring isofre-
quency and isobaric comparisons among groups. During
each experimental session, pressure and diameter signals
were measured under dynamic conditions, displayed in real
time, digitised every 5ms, and stored for oﬄine analysis.
All recorded samples included at least twenty consecutive
beats. At the end of each experiment, in order to calculate
the conduit strain, a recording of the nonpressured midwall
radius (R0) was computed as the radius at 0mmHg [17].
Afterwards, segments were weighed and instantaneous wall
thickness (h) was calculated as
h = re −ri,( 2 )
where re and ri are the external and internal radius,
respectively.
The internal radius (ri) was calculated as:
ri =

r2
e −
V
π ·L
,( 3 )
where L is the in vivo length, and V is the conduit volume,
calculated using the segment weight and assuming a tissue
density (ρ)o f1 . 0 6g ·cm−3.
PWV was calculated using the Moens-Korteweg equa-
tion:
PWV =

EINC ·h
2 ·R ·ρ
,( 4 )
where EINC is the incremental elastic modulus and R is the
midwall radius [17].
In order to determine EINC, values of the conduit strain
(ε) and circumferential stress (σ) were calculated as
ε =
R
R0
,( 5 )
σ =
2P(re ·ri)
2
r2
e −r2
i
·
1
R2,( 6 )
where R0 is the non-pressured midwall radius obtained as
described above and P is the intraluminal pressure. Finally,
the stress-strain loop was constructed in all cases; this
allowed us to obtain the σ-ε purely elastic relationship, using
the hysteresis-elimination method. EINC was calculated as
EINC = 0.75
dσ
dε
,( 7 )
where dσ/dε is the ﬁrst derivative of σ respect to ε [17].
Finally, the CHP native artery-vascular substitute biome-
chanical mismatch (BM), expressed as a percentage, was
calculated as [12, 13]
BM =
PWVCHP −PWVVascular substitute
PWVCHP +PW V Vascular substitute
· 100. (8)
The BM values range between 100 and −100. A null BM
(BM = 0) represents an optimal coupling or matching
(i.e., vascular substitute and native vascular pathway with
identical biomechanical behaviour), while values far from
0 indicate increasing mismatch. A negative value indicates
that the vascular substitute is stiﬀer than the native vascular
pathway; a positive value indicates that the native vascular
pathway is stiﬀer than the vascular substitute.
3. Statistics
Measuredandcalculatedvalueswereexpressedasmeanvalue
± SD. A P<0.05 was considered statistically signiﬁcant.
Unpaired t-test and ANOVA plus Bonferroni tests were
employed. The statistical software used was the SPSS 17.0
(Chicago, IL, USA).
4. Results
Both noninvasive and in vitro studies, performed according
to the methodology described above, provided high quality
biological wave recordings. No technical mistakes occurred
during data acquisition. As was expected, the studied CHP
showed an increased aortic stiﬀness level, evidenced by a
higher carotid-femoral PWV than the expected for age and
bloodpressure-matchedhealthyEuropean[24,25]orSouth-
American [26] subjects. There were not signiﬁcant carotid-
femoral PWV diﬀerences across the groups (Table 1).
Patients with the vascular access for haemodialysis in
the forearm and those with the vascular access in the
upper arm showed nonsigniﬁcant diﬀerences in terms of
age, height, weight, and waist and hip perimeters (Table 1).
Similarly, with the exception of PTH levels, there were no
diﬀerences between the groups regarding biochemical, and
haemodynamic parameters (Table 1). There were not signif-
icant diﬀerences in eGFR levels across the groups (Table 1).
Gender comparison of clinical characteristics, biome-
chanical parameters, and arterial pressure values showed
only signiﬁcant diﬀerences (P<0.05) in terms of height,
haematocrit, PTH, and haemoglobin levels (Table 1).
4.1. Carotid-Brachial Arterial Stiﬀness: Vascular Access Loca-
tion and Gender Dependence. Regardless of the vascular
access location (upper arm or forearm), the carotid-brachial
PWV was lower in the upper limb with the vascular accessInternational Journal of Nephrology 5
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Figure 1: Comparison between carotid brachial pulse wave velocity (PWV) values (mean ± SD) obtained in upper limbs with arteriovenous
ﬁstulae (AVF) with respect to their contralateral intact limbs (∗P<0.05). The analysis discriminates between vascular accesses performed at
upper arm and forearm level (a), and between genders when the vascular access was performed at upper arm level (b).
(P<0.05) than in the contralateral one (i.e., the limb with
intact arteries). When AVF was performed in the forearm,
a statistically signiﬁcant diﬀerence was observed between
contralateral upper limbs (10.50 ± 0.47 versus 11.30 ±
0.36m/s); a similar ﬁnding was conﬁrmed when the AVF
was constructed in the upper arm (9.60 ± 0.61 versus 11.30
± 0.78m/s) (Figure 1(a)). The mentioned diﬀerences were
greater (P<0.05) in CHP with the AVF in the upper arm
than in those with the vascular access in the forearm (−17.00
± 5.18% versus −7.10 ± 2.29%) (Figure 2(a)).
The carotid-brachial PWV measured in intact upper
limbs (i.e., without AVF) of CHP described above was sim-
ilar, regardless of whether the AVF was performed in the
upper arm (11.30 ± 0.78m/s) or in the forearm (11.30 ±
0.36m/s) (Figure 1(a)).
When considering gender in the vascular stiﬀness anal-
ysis, it was observed that both male and female CHPs with
vascular accesses in the upper arm exhibited lower PWV
values (P<0.05) in the limb with the AVF than in its
contralateral intact limb (Figure 1(b)). More precisely, in
females, PWV values obtained in the carotid brachial path-
way where the AVF was performed were lower (P<0.05)
than in the contralateral intact limb (10.00 ± 0.67 versus
10.60 ± 0.57m/s); similar ﬁndings were observed in males
(8.70 ± 1.29 versus 12.60 ± 2.09m/s) (Figure 1(b)). The
mentioned diﬀerences were greater in males than in females
(−29.60 ± 9.36% versus −9.50 ± 4.15%) (Figure 2(b)).
4.2. Biomechanical Mismatch between Vascular Substitutes
and Native Arteries: Vascular Access Location and Gender
Dependence. Humanbrachialarteryhomograftsensuredthe
best BM values with native vessels (Table 2), regardless of
genderandvascularaccesslocation.Moreover,BMvaluesare
better in females than in males with AVF performed in the
upper arm. On the other hand, ePTFE prostheses showed the
worst BM values.
Analysing the biological alternatives included in Table 2,
we observed that the same graft can show very diﬀerent
values of BM. When comparing the native vessel-homograft
BM values obtained in the limb with the AVF with those of
thelimbwithintactarteries,therewerediﬀerences(P<0.05)
regardless if the AVF was performed in the upper arm
or in the forearm. Similar diﬀerences were found when
comparisons were made considering gender (Table 2).
Saphenous vein and femoral and brachial artery homo-
grafts showed lower values of BM with respect to native
vesselswhentheAVFwasperformedattheforearmlevelthan
those measured when the vascular access was constructed in
the upper arm (P<0.05), see Table 2(a). On the other hand,
when using carotid artery homografts, the opposite result
was obtained (P<0.05) (Table 2(a)). Finally, diﬀerences in
native artery-homograft BM were found between males and
females, regardless of AVF location (Table 2).
5. Discussion
We have recently demonstrated that in CHP, arterial stiﬀness
values measured in the arterial pathway of the upper limb
where the vascular access was constructed were lower than
those measured in its contralateral limb with intact arteries
(i.e., without vascular access) [1]. Continuing our project,6 International Journal of Nephrology
Table 2: Biomechanical mismatch among vascular substitutes and carotid-brachial pathways of CHP with AVF at the forearm or at the
upper arm region.
(a)
CHP with AVF in the forearm
(n = 20)
Mean ± SD
CHP with AVF in the upper arm
(n = 18)
Mean ± SD
Femoral artery homograft
Versus upper limb with AVF −17.00 ± 1.87 −21.60 ± 2.38 &
Versus upper limb without AVF −13.54 ± 1.49∗ −13.79 ± 1.52∗
Brachial artery homograft
Versus upper limb with AVF 1.13 ± 0.12 −3.65 ± 0.40 &
Versus upper limb without AVF 4.67 ± 0.51∗ 4.41 ± 0.49∗
Carotid artery homograft
Versus upper limb with AVF 15.77 ± 1.73 11.08 ± 1.22 &
Versus upper limb without AVF 19.21 ± 2.11∗ 18.96 ± 2.09∗
Saphenous vein homograft
Versus upper limb with AVF −16.63 ± 1.83 −21.24 ± 2.34 &
Versus upper limb without AVF −13.16 ± 1.45∗ −13.42 ± 1.48∗
ePTFE
Versus upper limb with AVF −78.18 ± 8.60 −79.97 ± 8.80
Versus upper limb without AVF −76.76 ± 8.44 −76.87 ± 8.46
(b)
CHP with AVF in the upper arm
Females
(n = 10)
Mean ± SD
CHP with AVF in the upper arm
Males
(n = 8)
Mean ± SD
Femoral artery homograft
Versus upper limb with AVF −19.44 ± 2.14 −26.16 ± 2.88$
Versus upper limb without AVF −16.76 ± 1.84∗ −8.29 ± 0.91∗$
Brachial artery homograft
Versus upper limb with AVF −1.39 ± 0.15 −8.47 ± 0.93$
Versus upper limb without AVF 1.38 ± 0.15∗ 9.95 ± 1.09∗$
Carotid artery homograft
Versus upper limb with AVF 13.30 ± 1.46 6.28 ± 0.96$
Versus upper limb without AVF 16.01 ± 1.76∗ 24.27 ± 2.67∗$
Saphenous vein homograft
Versus upper limb with AVF −19.07 ± 2.10 −25.81 ± 2.84$
Versus upper limb without AVF −16.39 ± 1.80∗ −7.91 ± 0.87∗$
ePTFE
Versus upper limb with AVF −79.14 ± 8.71 −81.64 ± 8.98
Versus upper limb without AVF −78.08 ± 8.59 −74.49 ± 8.19
Mean value ± standard deviation (SD) (%). CHP: chronically haemodialysed patients. The biomechanical mismatch (BM) level ranges between 100
and −100. A BM = 0 represents an optimal matching; values far from 0 indicate an increasing BM. A negative BM (from 0 to −100) indicates that the
vascular substitutes were stiﬀer with respect to the vascular pathway; a positive BM indicates the contrary.
Statistics.
∗P<0.05 with respect to upper limb with AVF, for the same vascular substitute and group of subjects.
&P<0.05 with respect to CHP with AVF at the forearm, for the same vascular substitute and upper limb.
$P<0.05 with respect to CHP with AVF at the upper arm in females, for the same vascular substitute and upper limb.International Journal of Nephrology 7
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Figure 2: Carotid brachial pulse wave velocity (PWV) diﬀerences (mean ± SD) between upper limbs with arteriovenous ﬁstulas (AVF) with
respect to their contralateral intact limbs. Diﬀerences obtained at forearm level were lower than those obtained at upper arm level (a). At
upper arm level, diﬀerences obtained in females were lower than those obtained in males (b) ∗P<0.05.
and using the same data set previously employed [1], and
new original clinical and experimental data and records, in
this work we analyse the carotid-brachial arterial stiﬀness
considering the vascular access location (upper arm or
forearm levels), and we analyse potential gender-related
diﬀerences. The main ﬁndings were as follows.
(i) First, the reduction in the carotid-brachial PWV
was greater in upper limbs with the vascular access
located in the upper arm.
(ii) Second, carotid-brachial PWV reduction in upper
limbs with vascular access was evidenced in males
and females CHP. When the AVF was constructed
in the upper arm, the arterial stiﬀness reduction was
greater in males.
(iii) Third, independently of the AVF location (i.e., upper
armorforearm),thevascularhomograftthatensured
the best BM was the brachial artery.
(iv) Fourth, the native vessel-vascular substitute BM
showed signiﬁcant diﬀerences, depending on the
gender and the upper limb considered (intact or
submitted to AVF construction).
PWV provides reliable information about arterial stiﬀ-
ness. In fact, at present, the carotid-femoral PWV is con-
sidered the gold standard technique to evaluate the regional
aortic stiﬀness using non-invasive methods [24]. Further-
more, in haemodialysed patients, carotid-femoral PWV is a
valuable mortality predictor [27–30]. Then, considering its
clinical meaning and that PWV is a simple, non-invasive,
robustand reproduciblemethod to evaluatearterialstiﬀness,
in this work we selected the use of PWV to determine
both the aortic (carotid-femoral PWV) and the upper limb
arteries (carotid-brachial PWV) stiﬀness. As it was expected,
in CHP, carotid-femoral PWV levels were higher than the
levels reported to evidence arterial subclinical alterations
[24–26].
In this study serum PTH levels were elevated (as is
common in CHP [31]), and diﬀerences in PTH levels were
found among groups (Table 1). However, no association was
found between PTH levels and carotid-femoral or carotid-
brachial PWV values. Then, diﬀerences in PTH levels could
not explain diﬀerences in carotid-brachial PWV reported
in our work. This ﬁnding agrees with previous works, in
which no association was found between serum PTH levels
and aortic stiﬀness or risk of death or cardiovascular events
[31, 32].
AVF have shown a beneﬁcial impact on aortic stiﬀness;
thisimprovementwouldbegreaterinpatientswithincreased
PWV before vascular access construction [33]. Additionally,
a reduction in the carotid-brachial stiﬀness in upper limbs
with AVF has been described [1]. In the ﬁrst case, the
arterial stiﬀness improvement has been associated to a blood8 International Journal of Nephrology
pressure reduction; in the second case, it would be due to an
arterial diameter increase, associated with AVF maturation.
In the present study we found that the carotid-brachial PWV
reduction was greater in patients with the AVF performed in
the upper arm than in those with the AVF in the forearm.
Therefore, we hypothesised that this reduction in arterial
stiﬀness associated with the existence of a vascular access
could result in an increase in arterial conduit and buﬀering
function and a reduction in left ventricle afterload [24].
However, the analysis of the diﬀerences in the arterial
stiﬀness reduction in terms of arterial function and cardiac
afterload changes and their meanings was beyond this work’s
scope.
Stiﬀness diﬀerences between limbs with the AVF in
the upper arm and those with the vascular access in the
forearm could be related with anatomical factors since the
brachial artery diameter is the highest among upper limb
arteries [3]. This is an important issue since the arterial
wall’s intrinsic properties (i.e., the elastic modulus) and
the vessel’s geometrical parameters (i.e., diameter) are main
determinants of the PWV (3)[ 24]. It is well known that
PWV and arterial diameter have an inversely proportional
relationship. Furthermore, the increase in diameter in vessels
used in the AVF construction constitutes an important issue
in the vascular access maturation process [34].
The AVF maturation and patency rates are lower in
female than in male haemodialysed patients [2, 3, 34]. The
origin of gender diﬀerences has not been yet elucidated. Sev-
eral studies have pointed out that the lesser maturation rate
in females would be due to the smaller diameter of vessels
in females, but factors other than vessel geometry could
also be involved in the maturation outcomes [2, 3, 34]. The
diﬀerences regarding AVF evolution described above could
be related to the gender dependence of age eﬀects on arterial
wall properties of upper limbs [35]. In 2000, a population
study demonstrated that brachial artery diameter increase,
with age in females than in males. Additionally, brachial
artery compliance values did not decrease with age, on the
contrary, a signiﬁcant increase was observed in females,
while among the male population no changes were observed
[36]. According to our results, the diﬀerences in the carotid-
brachial PWV between upper limbs with and without
AVF were signiﬁcantly higher in males than in females.
This original ﬁnding was observed only when the vascular
access was performed in the upper arm. The relationship
between gender diﬀerences in the vascular biomechanical
behaviour and in the AVF evolution should be analysed.
Regarding this, it has been stated that AVF maturation needs
compliant vessels that can dilate in response to blood ﬂow
increase[34].Therefore,genderdiﬀerences in vascular access
construction-associated changes in arterial stiﬀness could
contribute to the gender diﬀerences in the AVF evolution. As
a consequence of the ﬁndings reported in the present study,
further analyses should be performed in order to determine
the clinical relevance of vascular biomechanical properties
to predict the AVF outcome. More speciﬁcally, vascular
stiﬀness analysis should be included in studies on the low
performance of vascular accesses in females. Furthermore,
a longitudinal study including PWV measurements before
and after vascular access construction could contribute to
improve the knowledge of the AVF maturation process.
Gender and location of the vascular access (i.e., upper
arm or forearm) diﬀerences could be the origin of previously
reportedﬁndings,inwhichtheauthorspointedoutthatfore-
arm AVF have low success rate in chronically haemodialysed
females [3].
When analysing the carotid-brachial PWV changes in
hemodialysed subjects, at least three factors should be
considered for an adequate interpretation of our results. At
least in theory, the ﬁstulas/PTFE grafts maturation could
inﬂuence PWV values, since changes in AVF or grafts blood
ﬂow impedance associated with the maturation process
couldmodifytheupperlimblocalhemodynamicconditions.
For instance, changes in local haemodynamic conditions
could determine changes in the shear-stress applied to
the endothelial layer, which could modify the arterial wall
biomechanics through changes in the vascular smooth
muscle tone. Taking into account this, looking for stable
conditions, in our work the non-invasive studies were always
done in mature AVF. Second and related with that stated
above, it is noteworthy that our patients’ average length on
renal replacement therapy was 66 months. This time could
diﬀer (being higher or lower [31]) with the mean survival
length on hemodialysis in other centres and/or countries.
Then, the characteristics of our CHP could diﬀer from those
ofotherCHPgroups,whichshouldbeconsideredatthetime
of extrapolating our results to other patients. Furthermore,
the vascular changes associated with hemodialysis could
depend on the therapy length. Then, future works should
be developed to assess the potential association between the
subjects’ characteristics and/or the hemodialysis length and
the vascular changes in CHP.
According to our results, in CHP, the location of the
vascular access would result in diﬀerences in arterial stiﬀness
evaluated through PWV measurements in the carotid-
brachial pathway. In addition, as previously stated, the BM
between the native vessels and the vascular substitute to be
used in the vascular access construction could depend on
(a) gender, (b) the evaluated limb (with or without a VA),
and (c) location of the previous vascular access. Hence, the
patient’s characteristics and arterial biomechanical parame-
ters should also be evaluated. Nonetheless, our results show
that the brachial artery homograft would be the best vascular
substitute of choice, in terms of BM improvement.
Prostheses made out of ePTFE are widely used as a
second choice in peripheral vascular surgeries, among them,
vascular access construction. However, it is well known that
ePTFEvascularaccesseshavepoorlong-termoutcomes.This
could be attributed to the intimal hyperplasia development,
associated, among other factors, to the native vessel-ePTFE
high BM [6]. We have found that, independently of CHP
gender and arterial level in which the vascular access was
constructed, ePTFE prostheses always determined high BM
levels. Therefore, if vascular homografts were used instead
of ePTFE in the vascular access construction, the BM could
be signiﬁcantly diminished. Further research should beInternational Journal of Nephrology 9
undertaken in order to evaluate the clinical meaning of the
ﬁndings reported in this work.
We conclude that in CHP the carotid-brachial PWV
reduction was greater in patients with the AVF performed
in the upper arm than in those with the AVF in the forearm.
Additionally, when the AVF was constructed at upper arm
level,thearterialstiﬀnessreductionwasgreaterinmalesthan
in females. Finally, the native vessel-vascular substitute BM
could be minimized considering: (a) the histological type
of vascular homograft, (b) CHP gender, (c) vascular access
location (i.e., upper arm or forearm), and (d) existence of a
previous vascular access.
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